Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2021-01-17 Share Issue/Capital Cha…
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
Appendix 3G 12 pages 253.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G form submitted to the Australian Securities Exchange (ASX) regarding the notification of issue, conversion, or payment up of equity securities. It details the issuance of unquoted securities under an employee incentive scheme, including specifics such as the number of securities, exercise price, expiry date, and whether they are being issued to key management personnel. The document is a regulatory announcement about securities issuance rather than a financial report, earnings release, or management discussion. It fits the category of Share Issue/Capital Change announcements, which cover new share issues or other capital changes. The document length is substantial and contains detailed information about the securities issued, confirming it is not merely a brief announcement or a report publication notice. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2021-01-17 English
Change of Director's Interest Notice - ID 5 pages 428.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y – Change of Director’s Interest Notice' and details changes in securities holdings by a director, including the number of securities held before and after the change, the nature of the interest, and the context of the change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure related to insider transactions. The content focuses exclusively on the director's personal share transactions and interests, with no financial performance data or company-wide reports. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length and detail confirm it is the actual notice, not just an announcement or certification. Therefore, the correct classification is DIRS.
2021-01-17 English
Release of Securities from Escrow 1 page 192.4KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement dated 7 January 2021 from Nyrada Inc regarding the release of securities from escrow. It references an earlier Appendix 2A announcement and confirms the release of securities on a specific date. The content is focused on a capital market event related to securities escrow release, which is a capital structure update. The document is brief (1727 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, nor an earnings release or management discussion. It is not a regulatory filing or certification. The nature of the announcement fits best under Capital/Financing Update (CAP) as it relates to securities and escrow release, which affects capital structure and shareholder securities status.
2021-01-06 English
Change in substantial holding 2 pages 199.2KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Notice of Change of Interests of Substantial Securityholder' and details changes in the holdings and voting power of a substantial shareholder, Eleanore Goodridge, in Nyrada Inc. It includes specific numbers of shares/CDIs held before and after the change, and the voting power percentages. There is no financial data, earnings information, or management discussion. The document is a notification about changes in significant share ownership levels, which fits the definition of 'Major Shareholding Notification' (MRQ). The document length is short and focused solely on this change, with no indication of other report types or announcements.
2021-01-05 English
57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study 5 pages 305.5KB
Regulatory Filings Classification · 90% confidence The document is a detailed announcement of preliminary efficacy results from an in vivo study of Nyrada's drug candidate NYX-PCSK9i. It includes scientific data, comparisons with existing treatments, study methodology, and future plans for further studies. The content is focused on research progress and drug development updates rather than financial results, regulatory filings, or corporate governance. There is no indication that this is an official financial report, audit, earnings release, or regulatory filing. It is a scientific and corporate update on drug development progress, typical of a press release or corporate announcement about research milestones. Given the nature of the content and the absence of financial statements or regulatory compliance information, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2020-12-20 English
Appointment of New Auditor 1 page 180.4KB
Board/Management Information Classification · 95% confidence The document announces the appointment of a new auditor for Nyrada Inc, referencing compliance with Listing Rule 3.16.3. It is a formal announcement about a change in auditor following a tender process after the annual audit for the period ending 30 June 2020. The document does not contain any financial statements, audit results, or detailed audit reports. It is a corporate announcement about management changes related to auditors, which fits best under Board/Management Information (MANG) as it concerns a key management-related appointment. The document length is short (1766 characters), and it is not a report or detailed audit information, so it is not an Audit Report (AR) or Annual Report (10-K).
2020-12-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.